Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma
Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further about how management of hepatocellular carcinoma differs across stages.
Transcript
This video transcript has not been proofread or edited and may contain errors.
Dr Josep Llovet:
So hepatocellular carcinoma is a major health problem globally. Is the second cause of cancer-related death, and there are around 1 million cases globally. Around 30% of the patients are diagnosed at an earlier stage, and are potentially treated with curative therapies, resection, liver transplantation, and local ablation.
Then, 20 to 30% of the patients are diagnosed at intermediate stage. And currently the standard of care is transarterial embolization. And with the LEAP-012 study, we are proposing to switch the standard of care to lenvatinib, pembrolizumab, and TACE instead of TACE. And then, around 40 to 50% of the cases are diagnosed at advanced stages of the disease. Meaning, they have vascular invasion, lymph node involvement or extrahepatic spread, or ECOG performance status 1/2. And with these patients there have been a revolution in the management, even in the last 15 years. In front-line we have immune-based regimes, like atezolizumab plus bevacizumab, and durvalumab plus tremelimumab, and nivolumab plus ipilimumab. And for those patients that have contraindications for immune-based regimes, the current standard of care is lenvatinib or sorafenib.
In patients progressing to these lines of therapy, both regorafenib and cabozantinib, and also a monoclonal antibody, ramucirumab, have shown also to impact in survival. So this gives you a picture of the current management of the disease throughout different stages.